ACOG (Alpha Cognition) EBITDA Margin %: -228.24% (As of Mar. 2026)

What is Alpha Cognition EBITDA Margin %?

Alpha Cognition ACOG +0.08% 32 EBITDA Margin % is -228.24% as of Mar. 2026. GuruFocus rates ACOG with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Alpha Cognition ranks worse than 63.81% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alpha Cognition's EBITDA for the three months ended in Mar. 2026 was $-8.07 Mil. Alpha Cognition's Revenue for the three months ended in Mar. 2026 was $3.53 Mil. Therefore, Alpha Cognition's EBITDA margin for the quarter that ended in Mar. 2026 was -228.24%.

Alpha Cognition (NAS:ACOG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Alpha Cognition EBITDA Margin % Related Terms

Alpha Cognition EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Alpha Cognition's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Cognition EBITDA Margin % Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

-220.36

Alpha Cognition Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															-113.59	-345.30	-186.17	-282.24	-228.24

ACOG vs GNLX, VTVT, CRDF: EBITDA Margin % Comparison

For the Biotechnology subindustry, Alpha Cognition's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Cognition EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's EBITDA Margin % falls into.

Save Embed

32GF Score

Alpha Cognition Inc ACOG

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Alpha Cognition EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Alpha Cognition's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-22.521	/	10.22
	=	-220.36 %

Alpha Cognition's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-8.066	/	3.534
	=	-228.24 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -228.24% mean?

Alpha Cognition (ACOG) has a EBITDA Margin % of -228.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alpha Cognition and its competitors. According to the industry distribution chart, Alpha Cognition ranks #603 out of 945 companies in the Biotechnology industry, placing it in the top 63.8%.

Is Alpha Cognition's EBITDA Margin % too high?

Alpha Cognition's current EBITDA Margin % is -228.24%. Based on the distribution chart, Alpha Cognition ranks #603 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alpha Cognition has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Alpha Cognition's EBITDA Margin % compare to GNLX and VTVT?

According to the Biotechnology industry distribution chart, Alpha Cognition ranks #603 out of 945 companies for EBITDA Margin %. This places Alpha Cognition in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alpha Cognition and its competitors. Alpha Cognition's current EBITDA Margin % is -228.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Alpha Cognition stock overvalued right now?

Alpha Cognition (ACOG) has a current EBITDA Margin % of -228.24%. The current EBITDA Margin % is -228.24%. Alpha Cognition's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Alpha Cognition (ACOG), the current EBITDA Margin % is -228.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alpha Cognition Business Description

Industry Healthcare Biotechnology

Comparable Companies GNLX VTVT CRDF GUTS BDTX SPRB ALPS ONCY HURA AGEN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 7N70:Germany

Address 1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8

Website https://www.alphacognition.com

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

32GF Score

Get the complete analysis for ACOG

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.59

Price

View ACOG Analysis

See EBITDA Margin % data for all stocks →